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Abstract
Background: Human Noroviruses (NoV) are the major cause of acute nonbacterial gastroenteritis and the leading cause of
outbreaks of gastroenteritis worldwide. Genotype II-4 (GII-4) NoV has been shown to spread rapidly and is the most
commonly detected strain worldwide, particularly in association with outbreaks. Previously, we have shown that circulating
GII-4 NoV strains exist as populations of selectively neutral variants, and that the emergence of epidemic GII-4 NoV strains
correlated with mutations in at least two key sites (Sites A and B) within the P2 domain of the surface exposed major capsid
protein (VP1).
Methodology: We developed a rapid pyrosequencing method for screening of the two Sites A and B and a homology based
modelling system was used to predict the effects of amino acid substitutions at these sites on the antigenic properties of
the virus (defined as surface motif types).
Principle Finding/Conclusion: Here, we describe the characterisation of amino acid diversity at Sites A and B for 1062 GII-4
NoV strains from clinical specimen associated with outbreak of gastroenteritis (2000–2011) and 250 GII-4 NoV sequences
from Genbank. Our data identified a high diversity of different Site A and B site combinations at amino acid level and amino
acid diversity was higher at Site B than Site A. Site A motifs could be grouped into 3 clusters based on similar surface motif
types. We predict that Site A is a major epitope on the virus surface, responsible for defining the antigenic profile, and a
more subtle role for Site B, maintaining minor antigenic variation within the virus population.
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Introduction
Norovirus (NoV) is the leading cause of acute viral gastroen-
teritis in humans worldwide, affecting people of all ages [1,2]. A
study into community cases of infectious intestinal disease in the
UK estimated that 3 million episodes of gastroenteritis each year
are attributable to NoV [1]. Outbreaks of NoV gastroenteritis are
often reported in semi-closed environments (such as schools, the
military or cruise ships), but have the greatest impact and occur
with highest frequency in health care settings, particularly
hospitals and nursing homes. In 2009, over 2300 outbreaks of
NoV gastroenteritis in hospitals in England affected over 24,000
patients (HPA, http://www.hpa-bioinformatics.org.uk/
noroOBK/).
Gastroenteritis associated with NoV is usually mild and self-
limiting but can have a serious impact on high risk groups such as
elderly or immunocompromised people, causing prolonged
morbidity and contribution to excess mortality [3,4,5]. Typically
the illness presents as vomiting and/or diarrhoea, with onset 12–
48 hours after infection, and symptoms generally last for 12–
48 hours.
The Norovirus genus is one of four genera in the Caliciviridae
family, which are small, non-enveloped, single-stranded (ss)RNA
viruses. The NoV genome is ,7.5 kb and is organised into three
open reading frames (ORF): ORF1 encodes a polyprotein that is
cleaved into smaller non-structural proteins; ORF2 and ORF3
encode the major (VP1) and minor (VP2) capsid proteins,
respectively.
There are 5 NoV genogroups (GI–GV), based on the VP1
sequence, and these are further subdivided into multiple genotypes
[6]. The majority of human NoV strains are found in genogroups
GI and GII, and genogroup II-genotype 4 (GII-4) strains and are
the most commonly detected strains worldwide and are the most
frequent NoV associated with outbreaks in healthcare settings [2].
The ability of NoV to cause large and widespread outbreaks is
associated with several factors. The infectious dose of NoV is
predicted to be very low [7], and it is transmitted via a faecal-oral
route through direct contact, aerosol droplets or fomites. The
immunity generated following NoV infection wanes rapidly
(approximately 6 months), and any cross-protective immunity is
likely to be limited [8].
A number of factors have been identified that may influence the
susceptibility in the population to NoV infection. Early population
studies suggested that a host genetic factor may have a role in
determining individual host susceptibility to NoV infection [9,10].
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Two host factors implicated in the susceptibility to NoV are histo-
blood group antigens (HBGAs) and host immunity.
The HBGAs are terminal carbohydrates, whose stepwise
synthesis is catalysed by a family of glycosyltransferase enzymes.
The expression of HBGAs differs among tissues: ABH and Lewis
antigens are expressed on the epithelia of tissues that are in contact
with the external environment, such as the respiratory and
gastrointestinal tracts. HBGA molecules are also secreted into the
saliva of some individuals. As HBGAs are expressed differently
across the population, based on an individual’s genetic profile,
these have been postulated as susceptibility factors, and it has been
proposed that these are utilised as attachment molecules by NoV
[11]. Studies suggest that different NoV genotypes have different
HBGA recognition profiles [11,12] and that within a single
genotype HBGA recognition profiles can change over time
[13,14].
The interactions between virus and host immune system is likely
to be another key factor influencing the population susceptibility to
NoV. The genetic diversity observed among GII-4 NoV strains is
likely to be, at least in part, driven by selective immunological
pressure at a population level [14,15,16]. Genetic drift has been
shown to lead to the generation of diversity among GII-4 NoV
strains, and several positions – mostly located within the
hypervariable region (P2 domain) – have been described as
potential epitopes which are likely to be subject to immune
selection [14,15,16].
Previously, we have shown that GII-4 NoV strains exist as
populations of selectively neutral variants, and that periodically,
the emergence of novel GII-4 NoV strains associated with
epidemic waves of gastroenteritis correlated with mutation in at
least two key sites within the P2 domain [15,17]. These two motifs
(A and B) in the P2 domain, each three amino acids in length,
localise to surface exposed loops on the capsid surface and function
as GII-4 variant-specific epitopes (Figure 1) [18].
In this study we aim to further characterise the diversity at
hotspot Sites A and B among circulating GII-4 NoV strains. We
developed a rapid pyrosequencing method for screening of the two
sites, which was used for monitoring sequence diversity of Site A
and Site B for a panel of 1062 GII-4 NoV clinical specimens.
Methods
Clinical Samples
A total of 1062 faecal samples representative of NoV-confirmed
outbreaks occurring in England between 2000–2011 were selected
from an archive held at the Enteric Virus Unit, Health Protection
Agency, London UK. Clinical samples were prepared as 10%
suspensions in a balanced salt solution (Modified Eagles Medium,
Gibco, Life Technologies, Paisley, UK).
Nucleic Acid Extraction and Reverse Transcription
Total nucleic acid was extracted from a 200 ml aliquot of the
suspension using the QIAxtractor automated nucleic acid extrac-
tion platform (QIAGEN Ltd., Crawley, UK) and the VX Reagent
& Plasticware kit (QIAGEN). Complementary DNA (cDNA) was
generated by reverse transcription; extracted nucleic acid was
incubated in the presence of 50 pmol of poly(T) primer, Tris-HCl
buffer (pH 8.3), 5 mM MgCl2, 1 mM each dNTP and 200U
SuperScript-III reverse transcriptase (Life Technologies). The
reverse transcription reaction was performed at 42uC in a water
bath.
Amplification of P2 Domain
The NoV P2 domain was amplified by polymerase chain
reaction (PCR) as previously described [15,19]. For pyrosequenc-
ing, biotinylated amplicons were generated using a biotinylated
reverse primer.
Pyrosequencing
Pyrosequencing was performed using the QIAGEN PyroMark
ID platform according to the manufacturer’s instructions. Briefly,
biotinylated amplicons were immobilized on streptavidin coated
sepharose beads, denatured and washed to generate single
stranded (ss)DNA using the PyroMark Vacuum Prep Workstation
(QIAGEN). The ssDNA was then released to the PSQ plate
containing annealing buffer and sequencing primer, which was
briefly heated then cooled to allow sequencing primer annealing.
Pyrosequencing reactions were performed using PyroMark Gold
Q96 SQA reagents and the PyroMark ID instrument (QIAGEN)
with 100 de-novo nucleotide dispenses. Negative controls were
also included in the runs. Resulting pyrograms were automatically
analyzed using the PyroMark analysis software. Generated
sequences were exported in FASTA format and analysed as
described below.
The following pyrosequencing primers were designed for this
study:
Pyro_Site A1:39-TCTGCTGTCAACATCTGC-59
Pyro Site B1:39-AAAACACGAAATTCACCCCAGTCG-
GYGT-59
Pyro_Site B2:39-CAAAACACGAAATTCACCCCAGY-59
Genbank Data & Sequence Bioinformatics
A total of 250 GII-4 NoV sequences available from Genbank
were also included in the analysis. These were a mixture of full-
length genome, full-length capsid (ORF2) and partial capsid
Figure 1. Location of Site A and Site B in the GII-4 NoV P2
domain. The NoV genome has three open reading frames (ORF1, 2, 3)
and the major capsid protein (VP1) is encoded by ORF2. The VP1
protein has three main domains: an N-terminal domain (N), the highly
conserved shell domain (S), and the protruding domain (P) which forms
surface exposed spikes on the virus surface, which is further subdivided
into hypervariable P2 domain (P2) and the more conserved P1 domain
(P1). Previously, we identified two antigenic sites in the hypervariable
P2 domain of the GII-4 NoV capsid protein [15]. Site A (shown in red) is
comprised of consecutive amino acid residues 296–298. Site B (shown
in blue) is comprised of continuous amino acid residues 393–395.
Amino acid position numbering relative to prototype strain Lordsdale/
1993/UK (Accession Number: X86557), residues mapped onto the
surface of GII-4 NoV strain VA387 P-domain crystal structure (PDB
Number 2OBS) described by Cao et al [22].
doi:10.1371/journal.pone.0041625.g001
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sequences. A complete list of accession numbers for the samples
included are provided in Table S1.
Where full-length P2 domain amplicons were generated and
sequenced in place of pyrosequencing data, sequence analysis was
performed using Bionumerics v6.1 (Applied Maths, Kortijk,
Belgium). Amino acid sequences were deduced from nucleotide
sequences using BioEdit [20].
Throughout, amino acid motifs are designated by standard
IUPAC single-letter amino acid code.
Homology Modelling
For homology modelling, programs SPDBV [21] and NOC 3.1
(http://noch.sourceforge.net/) were used to model amino acid
changes at Site A (amino acid positions 296–298) and Site B
(amino acid positions 393–395) within the P2 domain (Figure 1).
Modelling used the published crystal structure of GII-4 NoV strain
VA387 (PDB: 2OBS) [22] as a template. Changes to the predicted
surface area profile of the P2 domain model were quantified (in A˚2)
and numerical values obtained were plotted.
Results
In this study we determined the amino acid diversity at Site A
and Site B in the P2 domain of GII-4 NoV strains (Figure 1) from
1062 clinical specimens associated with outbreaks of gastroenteritis
in the UK during the period 2000–2011, and an additional 250
GII-4 NoV isolates from the period 1974–2009 available from
Genbank (Table S1).
From the 1312 GII-4 NoV P2 domain sequences, we
identified 23 unique Site A amino acid motifs and 41 unique
Site B amino acid motifs, and these were found as 82 different
Site A/B amino acid motif combinations. The frequencies of
detection of each Site A/B amino acid motif combination are
shown in Figure 2.
Only 5/82 (6%) of Site A/B motif combinations were detected
with a frequency .5% (Figure 2). During the analysis period, 4
strain replacement events were observed where the Site A/B
amino acid motif combination detected in more than 60% of
isolates changed (Figure S1). The first replacement event occurred
2001–2002, when the motif combination [SHD,N–N] was
replaced almost entirely by [THN,NGT]. This motif combina-
tion then dominated until 2004 when it was replaced by
[TQN,STT], and in 2006, this motif was succeeded by motif
combination [TQE,STT]. By 2008, [TQE,STT] had been
replaced by [SRN,STT].
In order to understand the phenotypic characteristics of the Site
A/B amino acid motifs detected, we used homology modelling to
map these sites onto GII-4 NoV strain VA387 [22] and predict the
Figure 2. Detection frequencies of Site A/B motif combinations. In total, we detected 23 Site A and 41 Site B motifs in 82 combinations
during the analysis period. In 2001–2002 the motif combination [SHD,N–N] (black bar) was replaced by [THN,NGT] (dark green bar). This motif
combination dominated until 2004 when it was replaced by [TQN,STT] (hatched black & blue bar), and in 2006, this motif was succeeded by motif
combination [TQE,STT] (red & orange hatched bar). By 2008, [TQE,STT] had been replaced by [SRN,STT] (grey bar). The total numbers of strains
per year are given above the columns. Shaded columns highlight periods of high NoV activity in 2001/2002 (red), 2005/2006 (green) and 2009/2010
(blue). Amino acid motifs designated by standard IUPAC single-letter amino acid code. For more information on strain replacement events, see
Figure S1.
doi:10.1371/journal.pone.0041625.g002
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effects of the detected Site A/B motif combinations on the virus
structure around Site A and Site B. The data for predicted surface
area profiles at each site were plotted to produce predicted surface
area motifs (Figure 3).
Analysis of the amino acid motifs at Site A by homology
modelling revealed that the majority (n = 19/23, 82.6%) belonged
to one of three surface motif types (SMT-1, -2 and -3, Figure 3A).
Some Site A amino acid motifs detected 2007–2009 could not be
allocated into a specific SMT group (orphan motifs, n = 4).
Amino acid motif diversity was higher at Site B than at Site A,
and a similar analysis of the amino acid motifs at Site B by
homology modelling did not identify any grouping of Site B amino
acid motifs, and so no surface motif types could be defined for this
site (Figure 3B). However, it was noted that among the 41 unique
Site B amino acid motifs detected, the motif [STT] was the most
frequently detected (785/1312, 60%), and was detected in .40%
of samples from 2004 onwards (Figure 4).
In the period from 2000 to 2005, the majority of GII-4 NoV
isolates had predominantly type-1 surface motifs (SMT1)
(Figure 5). Type-2 surface motifs (SMT2) were first detected in
2005, and in 2006 these displaced strains with SMT1. This change
in SMT coincided with a period of high NoV activity in 2005/
2006. SMT2 declined in subsequent years, and by 2010 were no
longer detected. Type-3 motifs (SMT3) had been detected with
very low frequency before 2000, and did not become dominant
until 2007. After 2007, SMT3 displaced SMT2 as the dominant
Site A surface motif, and remained dominant until 2011
(Figure 5A).
Type-1 surface motifs (SMT1) were most commonly found in
association with one of three Site B amino acid motifs, namely [N–
N], [NGT] and [STT] (Figure 5B). Prior to 2002, [N–N] was most
frequently detected in association with SMT1, then between 2002
and 2004 [N–N] was replaced by [NGT], and this motif was
succeeded by [STT] between 2004 and 2007, when strains with
SMT1 motifs became infrequently detected.
Both SMT2 and SMT3 strains were most commonly detected
in association with the [STT] amino acid motif at Site B
(Figure 5C & D, respectively). In 2009 the number of SMT3
strains detected in association with [STT] at Site B declined,
and was accompanied by a concomitant increase in the diversity
of the Site B amino acid motif associated with SMT3. This
event coincided with a period of high NoV activity in the
winter of 2009/2010.
Figure 3. Predicted surface motif types (SMT) of (A) Site A motifs, and (B) Site B motifs. Predicted surface area profiles were generated
and the surface area values (A˚2) of key amino acid residues were plot graphically. Similar profiles were grouped together as surface motif types. (A)
Predicted surface motif types for Site A (amino acid residues 296–298) revealed three clusters of profile types: surface motif type 1 (red) detected
2000–2011; surface motif type 2 (green) detected 2004–2009; surface motif type 3 (blue) detected 2000–2011. (B) Predicted surface area profiles for
Site B (amino acid residues 293–395) did not show definitive profiles, and surface motif types could not be defined from this data.
doi:10.1371/journal.pone.0041625.g003
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Discussion
We previously identified two sites (Site A and Site B) within the
hypervariable P2 domain of the NoV major capsid protein VP1
that undergo selective amino acid changes that coincide with the
appearance of epidemiologically significant GII-4 NoV strains in
the population [15] Furthermore, these two sites were sufficient to
define strain-specific GII-4 antibody-antigen interactions [18].
Our data, together with that of others contributes to a growing
body of evidence that suggests novel GII-4 NoV antigenic variants
emerge in response to selective pressure from the host population
[14,15,16,23,24].
In this paper, we describe the characterisation of the amino acid
motifs at Site A and Site B of 1312 GII-4 NoV strains; 1062
nucleotide sequences derived from strains collected in England &
Wales in the period from 2000 to 2011, with greater number of
samples available for testing from 2004 onwards, and 250 GII-4
NoV sequences available from Genbank collected between 1974
and 2009 (Table S1) were also included in the analysis.
We explored the value of modelling the predicted surface area
derived from the different amino acid substitutions at sites A and B
as predictors for significant changes that correlated with the
emergence and/or switch of epidemic strains. During the analysis
period, three years were associated with higher-than-average NoV
activity in the UK: 2002, 2006 and 2009. This analysis showed
that for Site A, three major surface area motif types (SMTs) could
be defined over the analysis period. In contrast, the diversity at
Site B could not be used to define SMTs in the same way as for
Site A. Plotting the frequency of SMT associated with site A and
the diversity associated with site B showed that years of higher-
than-average NoV activity were associated with: (i) a switch in the
most frequently detected Site A surface motif type, or (ii) an
increase in the amino acid diversity observed at Site B (Figure 5).
Here, we propose a model of antigenic evolution for GII-4 NoV
strains based on sequence diversity at both Site A and Site B, and
epidemiological trends observed in between 2000 and 2011.
We predict that Site A is a major epitope on the virus surface,
responsible for defining the antigenic profile of GII-4 NoV strains
belonging to different neutral networks of viruses, described
previously [15]. Although a significant degree of amino acid
diversity is seen at Site A, most of the diversity seen is likely to be
phenotypically neutral, as defined in terms of surface area, with
the vast majority of strains belonging to only 3 distinct SMTs,
termed 1, 2 or 3. Interestingly, the emergence of an SMT
correlated with the epidemic waves, and was accompanied by
displacement of the previously dominant SMT. Therefore SMTs
at Site A define three different ‘‘epochs’’ of NoV activity between
2000 and 2011.
Although the diversity observed at site B could not be correlated
with discreet SMTs, we observed periodic increases in amino acid
motif diversity at this site, and this coincided with periods of high
NoV activity (Figure 5). We predict that Site B is a minor epitope
on the virus surface, and that diversity at this site is associated with
maintaining sufficient antigenic diversity within the virus popula-
tion allowing for the persistence of GII-4 strains in the pre-exposed
human population between epidemic waves or NoV ‘‘epochs’’.
The level of diversity at Site B may influence the year-on-year
Figure 4. Frequencies of detection of Site B motifs 2000–2011. A single motif [STT] (green) was the most frequently detected throughout the
analysis period. Between 2008 and 2009 the amount of diversity at Site B increased, with 15 and 13 different motifs detected, respectively. Amino acid
motifs designated by standard IUPAC single-letter amino acid code.
doi:10.1371/journal.pone.0041625.g004
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epidemics observed in successive winter seasons, in contrast to Site
A in which significant changes occur more sporadically.
The large NoV epidemic described worldwide in 2002
coincided with the emergence of a drastic change at Site B in
the form of an amino acid insertion, in the context of strains of
SMT1 at Site A. This significant change appears to clearly
correlate with the pandemic event, but GII-4 strains of SMT1
continued to dominate until the 2005/6 winter epidemic, possibly
though the diversity emerging at Site B. The epidemic in 2006
correlated with a switch to SMT2, which appeared to vanish more
rapidly than SMTs 1 and 3, and this may be explained though the
lower degree of diversity seen at the Site B associated with the
strains of SMT2. Finally, although SMT3 had been circulating at
relatively low levels for a decade, it did not cause a large epidemic
wave until 2009, but only when it was found in association with
the highest level of diversity at Site B.
This therefore suggests that both these sites contribute to
immune evasion and hence the persistence of GII-4 strains in the
human population. It is also noteworthy that although there are
epidemic events which are described concomitantly worldwide,
such as those in 2002 and 2006, which could be defined as NoV
pandemics, there are other high NoV activity years that appear to
be more localised. For example, an increase in NoV activity
described in the Netherlands [25] and Australia [26] was not
mirrored in the UK, whereas the increased NoV activity detected
in the UK in 2009 was not seen in other countries [27]. These
differences may be driven by the degree of diversity within Site B,
which may be responsible also for more localised epidemics. In
2009, a new GII-4 strain, termed New Orleans, emerged across
the USA [28]. This replaced the Minerva (2006b) GII-4 strain as
the most prevalent NoV strain in the USA, however, surveillance
did not report any increase in numbers of NoV outbreaks during
the 2009/10 winter following emergence of the novel New
Orleans strain [27,28].
We compared both a Minerva (2006b)-like strain (Hu/OSD-
CS/2006/USA, Accession Number: EU078417) and a 2009 New
Orleans-like strain (Hu/GII.4/New Orleans 1805/2009/USA,
Accession Number: GU445325) with our data set and found that
both strains had the same surface motif; SMT3. Given that the
population had recently been exposed to the Minerva (2006b)
strain, the majority of the population would have been protected
against the 2009 New Orleans strain that belonged to the same
antigenic cluster. In fact, both Site A and Site B motifs in these
strains were identical to each other, and to the dominant
[SRN,STT] strains detected in our analysis.
There is additional in vitro data supporting evidence for the
model of evolution and immune evasion proposed here. We have
previously demonstrated that variant-specific antigenic profiles of
Figure 5. Higher-than-average NoV activity correlates with
shift in detected Site A surface motif type and increased amino
acid diversity at Site B. (A) Frequency of detected surface motif
types (SMT) of Site A, indicated in red (SMT1), green (SMT2) and blue
(SMT3) (as in Figure 3) changes over the time period analysed. (B)
Frequency of SMT1 NoV strains with Site B motifs N-N (pink), NGT
(purple), STT (red), and all other Site B amino acid motifs detected
(dashed black). (C) Frequency of SMT2 NoV strains with Site B motif STT
(green), and all other Site B amino acid motifs detected (dashed black).
(D) Frequency of SMT3 NoV strains with Site B motif STT (blue), and all
other Site B amino acid motifs detected (dashed black). Shaded
columns highlight periods of high NoV activity in 2001/2002 (red),
2005/2006 (green) and 2009/2010 (blue). (E) Periods of high NoV are
defined by the epidemiological trends observed over time. The data
shown here presents epidemiological data (number of NoV-positive
laboratory reports) for the period from 2007 to 2011 for England &
Wales. Prior to 2007, the data is not comparable due to differences in
reporting rates, and so is not shown. A clear increase in NoV-positive
laboratory reports is seen in 2009/2010, indicating an epidemiological-
ly-defined period of high NoV activity. Amino acid motifs designated by
standard IUPAC single-letter amino acid code.
doi:10.1371/journal.pone.0041625.g005
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GII-4 NoV strains can be defined by the amino acid residues at
Site A and Site B [18]. Mutation of Site A was sufficient to entirely
abolish mAb recognition of its homologous VLP, whereas
mutation at Site B resulted in a significant reduction in mAb-
VLP recognition was observed, but not complete abolishment of
binding [18].
Data from other studies also supports our conclusion that Site A
and Site B have important roles in defining the antigenic profile of
GII-4 NoVs. Of the ,120 amino acids in the P2 domain,
relatively few are likely to be involved in defining key epitopes,
based on the work of a number of laboratories (Figure 6)
[18,29,30,31]. Comparison of the data from 5 different studies
coincides in assigning residues around positions 296–298 (Site A)
and 393–395 (Site B) as likely determinants of the antigenic
phenotype of the virus (Figure 6).
Fine resolution epitope mapping by systematic mutation of the
capsid protein revealed that residues comprising Site A, plus three
others within the P2 domain (Epitope A) define a key surface
epitope, and also that the residues comprising Site B (Epitope D)
are involved in modulating interactions between virus and histo-
blood group antigens (HBGAs) [29]. This is in agreement with
data from Shanker et al. [31] who describe two sites (Site 1 and
Site 2) in the P2 domain that influence the interactions between
the virus and HBGAs. In their study, using crystallographic
structural techniques, the authors found that conserved residues in
the P2 domain (Site 1) were involved in a definitive binding
interaction with conserved a-fucose residues among the Lewis
HBGAs – in agreement with an earlier study by Cao et al. [22] –
and that Site 2 (or Site B) was involved in stabilisation of the
HBGA interaction through binding of the b-galactose residue in
the HBGA molecule.
The data now available from different studies seems to suggest a
major role for the residues in and around Site A in defining a
dominant surface epitope [31]. The data presented here suggests
surface/structure changes at Site A are more restricted, concurrent
with the observation that these residues are involved in binding
contacts with Lewis HBGA molecules [18,29]. The structures
defined by amino acid residues at Site A must be under pressure to
maintain their receptor binding functions; therefore mutations that
alter the antigenic profile at this site but maintain receptor binding
functionality are likely to be successfully selected in the population
of circulating strains.
Data for Site B suggests a more subtle role in terms of defining a
surface epitope, but an important role in modulating the strength
of binding interactions with HGBA molecules [31]. The data
presented in this study is in agreement with these findings, as the
residues at Site B show much more plasticity than those at Site A.
Furthermore, successful Site A motifs are associated with a diverse
array of Site B motifs, suggesting that the virus uses the genetic and
antigenic flexibility at Site B to enhance and modulate interactions
with receptors and the immune system occurring at Site A.
Supporting Information
Figure S1 Observed GII-4 norovirus strain replacement
events. The figure shows the frequencies of detection in each year
for the five most commonly detected Site A/B motif combinations
(Figure 2). Strain replacement events (where the most frequently
detected Site A/B motif combination in that year was different
from that in the previous year) are indicated above the graph by
arrows. We observed four strain replacement events between
2001–2002, 2003–2004, 2005–2006 & 2007–2008.
(TIF)
Table S1 List of accession numbers for GII-4 norovirus
strains used in this study. A total of 250 GII-4 NoV
sequences from strains isolated 1974–2009 that were available
from Genbank were included in our analysis. These were a
mixture of full-length genome, full-length capsid (ORF2) and
partial capsid sequences.
(PPT)
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